98%
921
2 minutes
20
The specific genetic subtypes that gliomas exhibit result in variable clinical courses and the need to involve multidisciplinary teams of neurologists, epileptologists, neurooncologists and neurosurgeons. Currently, the diagnosis of gliomas pivots mainly around the preliminary radiological findings and the subsequent definitive surgical diagnosis (via surgical sampling). Radiomics and radiogenomics present a potential to precisely diagnose and predict survival and treatment responses, via morphological, textural, and functional features derived from MRI data, as well as genomic data. In spite of their advantages, it is still lacking standardized processes of feature extraction and analysis methodology among different research groups, which have made external validations infeasible. Radiomics and radiogenomics can be used to better understand the genomic basis of gliomas, such as tumor spatial heterogeneity, treatment response, molecular classifications and tumor microenvironment immune infiltration. These novel techniques have also been used to predict histological features, grade or even overall survival in gliomas. In this review, workflows of radiomics and radiogenomics are elucidated, with recent research on machine learning or artificial intelligence in glioma.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10938723 | PMC |
http://dx.doi.org/10.1186/s40644-024-00682-y | DOI Listing |
Zhong Nan Da Xue Xue Bao Yi Xue Ban
May 2025
Department of Geriatric Pulmonary and Critical Care Medicine, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders (Xiangya Hospital), Changsha 410008.
Objectives: Non-small cell lung cancer (NSCLC) is associated with poor prognosis, with 30% of patients diagnosed at an advanced stage. Mutations in the and genes are important prognostic factors for NSCLC, and targeted therapies can significantly improve survival in these patients. Although tissue biopsy remains the gold standard for detecting gene mutations, it has limitations, including invasiveness, sampling errors due to tumor heterogeneity, and poor reproducibility.
View Article and Find Full Text PDFClin Otolaryngol
September 2025
Department of Otolaryngology-Head and Neck Surgery, Galway University Hospital, Galway, Ireland.
Introduction: Radiomics offers the potential to predict oncological outcomes from pre-operative imaging, aiding in the identification of 'high risk' patients with sinonasal cancer who are at an increased risk of recurrence. This study aims to comprehensively review the current literature on the role of radiomics as a predictor of disease recurrence in sinonasal squamous cell carcinoma.
Methods: A systematic search was conducted in Medline, EMBASE and Web of Science databases.
Front Oncol
August 2025
Department of Imaging, Yantaishan Hospital, Yantai, Shangdong, China.
This systematic review evaluates the integration of radiomics, artificial intelligence (AI), and molecular signatures for diagnosing and prognosticating bone and soft tissue tumors (BSTTs). Following PRISMA 2020 guidelines, we analyzed 24 studies from 1,141 initial records across PubMed, Scopus, Web of Science, and Google Scholar. Our findings reveal that while radiomics-AI pipelines are well-developed for BSTT assessment - particularly using MRI (72% of studies) and CT (25%) with machine learning classifiers like random forests (42%) and CNNs (17%) - molecular data integration remains virtually absent.
View Article and Find Full Text PDFCancer Med
September 2025
Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China.
Background: Oncotype DX 21-gene assays are recommended for evaluating distant recurrence and guiding decisions on the use of adjuvant therapy in ER+/HER2- breast cancers. However, it cannot be widely applied due to the high cost and time consumption.
Purpose: To identify MRI radiomics signatures within tumor and peritumoral tissues associated with the 21-gene recurrence score (RS) and explore their value in predicting 5-year recurrence in young women with ER+/HER2- breast cancer.
Sci Rep
September 2025
Department of Neurosurgery, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, 518035, P.R. China.
Glioblastoma multiforme (GBM) is a lethal brain tumor with limited therapies. NUF2, a kinetochore protein involved in cell cycle regulation, shows oncogenic potential in various cancers; however, its role in GBM pathogenesis remains unclear. In this study, we investigated NUF2's function and mechanisms in GBM and developed an MRI-based machine learning model to predict its expression non-invasively, and evaluated its potential as a therapeutic target and prognostic biomarker.
View Article and Find Full Text PDF